HALO
Halozyme Therapeutics, Inc.
HALO has the edge over NVO overall, supported by stronger modeled upside and lower modeled downside.
NVO
Novo Nordisk A/S
NVO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
HALO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Under pressure |
HALO's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HALO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $101 | — |
| Cheap | 15x | $60.40 | -40% |
| Fair | 21x | $84.87 | -16% |
| Current | 25x | $101 | — |
| Expensive | 35x | $139 | +38% |
Historical ranges are pointers, not guarantees.
HALO's PE is in its fair range at 25x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over HALO in the historical PE scenario, which offers more potential upside but is not a forecast.
HALO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
HALO has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HALO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.06 | +151% |
| Q3 2026 | $4.00 | -16% |
| Q2 2026 | $3.42 | -22% |
| Q1 2026 | $2.85 | -24% |
| Q4 2025 | $2.56 | -25% |
| Q3 2025 | $4.75 | +58% |
| Q2 2025 | $4.37 | +70% |
| Q1 2025 | $3.76 | +56% |
| Q4 2024 | $3.43 | +63% |
HALO earned $4.00 per share over the past year, down 16% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
HALO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $493M | +39% |
| Q2 2026 | $481M | +48% |
| Q1 2026 | $376.7M | +42% |
| Q4 2025 | $451.8M | +52% |
| Q3 2025 | $354.3M | +22% |
| Q2 2025 | $325.7M | +41% |
| Q1 2025 | $264.9M | +35% |
| Q4 2024 | $298M | +30% |
HALO has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 60% | -1.7 points |
| Q2 2026 | 60% | -2.4 points |
| Q1 2026 | 49% | -4.5 points |
| Q4 2025 | -21% | -80 points |
| Q3 2025 | 62% | +5.3 points |
| Q2 2025 | 62% | +12 points |
| Q1 2025 | 53% | +4.7 points |
| Q4 2024 | 59% | +15 points |
HALO has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
HALO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $255.2M | +45% |
| Q2 2026 | $236.7M | +141% |
| Q1 2026 | $176.3M | +15% |
| Q4 2025 | $217.6M | +24% |
| Q3 2025 | $175.6M | +54% |
| Q2 2025 | $98.1M | +84% |
| Q1 2025 | $153.3M | +22% |
| Q4 2024 | $175.4M | +76% |
HALO has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
HALO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.4M shares |
| 1 year | +0.2% | +280K shares |
| 3 years | -8.6% | -11.5M shares |
| 5 years | -16% | -24.1M shares |
| Available history | -13% | -18.4M shares |
HALO has 123M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $67.3M |
| Q4 2025 | — |
| Q3 2025 | $38.9M |
| Q4 2024 | $250M |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $252.3M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over HALO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HALO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.2x | Elevated |
| Q2 2026 | 3.2x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 4.2x | High |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 2.1x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 2.5x | Moderate |
HALO's net debt is about 3.2 years of its operating earnings (EBITDA), up from 1.5 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over HALO on leverage, with a lower net debt burden relative to earnings.
HALO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 47.7 | Neutral |
HALO's weekly RSI is 51 (neutral) and its Stochastic is 48 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HALO PE vs Healthcare Sector
| Metric | HALO | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 2.6% below |
| PE % | 65 | 29 | 36 pts above |
HALO is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over HALO on valuation relative to its sector.
HALO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $114.6 | 12% below |
| 20 week MA | $103.0 | 2.3% below |
| 50 week MA | $82.3 | 22% above |
| 100 week MA | $71.8 | 40% above |
| 200 week MA | $57.6 | 75% above |
HALO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
HALO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.0 | $42.9 | +139% |
| 2021 | $42.9 | $40.2 | -6.2% |
| 2022 | $40.2 | $57.5 | +43% |
| 2023 | $57.5 | $37.0 | -36% |
| 2024 | $37.0 | $48.1 | +30% |
| 2025 | $48.1 | $68.9 | +43% |
| 2026 YTD | $68.9 | $100.7 | +46% |
HALO has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.